[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vertebrogenic-pain-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vertebrogenic-pain-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053806","intracept-minimally-invasive-procedure-for-vertebrogenic-back-pain-100053806",false,"NCT06827262","Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain","IMPROVE","Inclusion Criteria:\n\n* Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).\n* Signed a valid, IRB\u002FEC-approved informed consent form.\n\nExclusion Criteria:\n\n* Meets any contraindications per locally applicable Instructions for Use (IFU).","ALL","18 Years",{"count":19,"type":20},1500,"ESTIMATED","60 Months","OBSERVATIONAL","Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.",[25,26],"Chronic Low-back Pain","Vertebrogenic Pain Syndrome",[28,29,30],"Intraosseous basivertebral nerve ablation","Axial low back pain","Low Back Pain","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2025-03-26",{"date":39,"type":20},"2034-07",{"name":41,"class":42},"Boston Scientific Corporation","INDUSTRY",18,{"id":45,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":47,"keywords":48,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":53,"leadSponsor":54,"locationsCount":43},"100579666",{"count":19,"type":20},[25,26],[28,29,30],"2026-06-23",{"date":51,"type":35},"2026-06-24",{"date":37,"type":35},{"date":39,"type":20},{"name":41,"class":42},{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":5},"100626284","time-to-bbvna-relief-100626284","NCT07433634","Time to BBVNA Relief","Temporal Trends and Predictors of Clinical Response Following Basivertebral Nerve (BVN) Ablation: A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Diagnosis of chronic axial low back pain with vertebrogenic features\n* Scheduled for BVN ablation\n* Able to provide informed consent\n* Capable of participating in weekly virtual\u002Ftelephone follow-up for 8 weeks and in- person or remote follow-up at 3 and 6 months through 2 years\n\nExclusion Criteria:\n\n* Prior spinal neuromodulation therapy (e.g., spinal cord stimulation or intrathecal pump) within the past 6 months\n* Active substance use disorder or uncontrolled psychiatric illness that may interfere with participation\n* Cognitive impairment limiting ability to complete surveys or provide informed consent\n* Pregnancy\n* Incarceration or current status as a prisoner",{"count":63,"type":20},200,"Basivertebral nerve ablation (BVNA) is a minimally invasive procedure approved for vertebrogenic low back pain. While early studies support its efficacy, real-world evidence is still evolving, particularly regarding the trajectory of pain relief and functional improvement over time, and predictors of clinical response. This study aims to evaluate clinical outcomes longitudinally following BVNA and identify baseline predictors of response.",[30,26,66],"Basivertebral Nerve Ablation",[68,69,70,71,72,73],"Pain relief trajectory","Basivertebral nerve ablation","Vertebrogenic low back pain,","Responder phenotypes","Clinical Outcomes","Radiofrequency Ablation","2026-02-27",{"date":76,"type":35},"2026-03-03",{"date":78,"type":35},"2024-04-19",{"date":80,"type":20},"2026-10",{"name":82,"class":83},"Yale University","OTHER"]